Pulmonary Disease
Conditions
Keywords
Xenon, Xe-129, CT
Brief summary
The goal of this project is to establish a registry and biorepository of images and biological samples from subjects undergoing novel pulmonary imaging methods to be used for future research aimed toward identifying clinical applications of imaging methods and toward understanding the physiological significance of imaging biomarkers. This registry and biorepository will accelerate the development of these imaging techniques and may lead toward future clinical adoption of quantitative pulmonary imaging.
Detailed description
Imaging is increasingly used for the non-invasive assessment of pulmonary health. Alongside this increased usage, there is enhanced interest in quantitative imaging methods that provide robust, repeatable, and objective measures of lung structure and function. At the forefront of this effort is quantitative computed tomography (qCT). CT imaging is the gold standard for high-resolution imaging of pulmonary structure, and the underlying physics of CT imaging is highly amenable to quantitative analysis. In addition to qCT, MRI is garnering increased interest as a modality for pulmonary imaging. Like CT, MRI is non-invasive, and it has the additional advantage of being ionizing radiation-free, making it more suitable for repeat imaging and for use in pediatric patients. Traditionally, MRI was not often used for lung imaging due to several difficulties regarding the acquisition of quality images in the lungs. However, recent advances to pulmonary MRI methods have enabled the acquisition of high-quality images of pulmonary structure and function. These advances include the use of ultra-short and zero echo time (UTE and ZTE, respectively) MRI methods, as well as the use of gaseous contrast agents such as hyperpolarized 129Xe. Despite these advances in qCT and MRI methods, the clinical applications for these imaging techniques are often unclear. Moreover, as new techniques, many of the imaging biomarkers in use have been independently developed by multiple sites and thus require standardization. As such, there is an urgent need both to standardize imaging/analysis techniques and to determine optimal clinical applications for these novel quantitative imaging methods.
Interventions
None listed
Sponsors
University of Kansas Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* The participant is enrolling/has enrolled in a research study at the University of Kansas Medical Center that involves Pulmonary MRI and/or Pulmonary CT.
Exclusion criteria
* The participant declines to participate.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Collect Clinical Data | From Enrollment to 3 Months | Collect relevant medical history (including demographic information, diagnoses, medical tests, smoking history), for patients participating in pulmonary imaging research. |
| Establish a Biorepository | From Enrollment to 3 Months | Establish a collection of biospecimens from imaging subjects to foster an improved understanding of the physiological significance of imaging biomarkers. |
| Biospecimen Collection | From Enrollment to 6 Months | Correlate imaging biomarkers with biospecimens and physiological/vital signs data. |
| Collaborate | From Enrollment to 12 Months | Provide images and biospecimens to researchers working to develop analysis methods for pulmonary CT and MRI. Separate IRB approval, alongside appropriate data and/or materials transfer agreements will be needed for these studies. |
Countries
United States
Contacts
CONTACTCristal Monge
CONTACTAdam M Ruff, BS
PRINCIPAL_INVESTIGATORPeter J Niedbalski, PhD
Research Assistant Professor
STUDY_DIRECTORLuigi R Boccardi, MPH
Director of Pulmonary, Critical Care, & Sleep Research
Outcome results
None listed